News

Decapeptyl LP 22.5mg is available as 1-3 months sustained release formulations and also daily formulation. Decapeptyl releases hormone (GnRH) agonist analogue over a period of time. The company

The company has also reported that it has designed a Phase 1/2 clinical trial to evaluate the safety of ARQ 197 administered in combination with irinotecan and cetuximab

Reportedly, in 2006, Aradigm has sold all assets related to the Intraject needle-free injector technology (now rebranded as DosePro) to Zogenix in exchange for milestone and royalty payments.

As per the agreement, Genmab is expected to receive an up-front license fee of $4.5m and will be entitled to milestones and royalties on sales of zanolimumab. TenX

BTG has a licensing agreement with Beacon Pharmaceuticals for the marketing of DigiFab in Europe, and Beacon has sub-licensed DigiFab distribution in Switzerland to Proreo Pharma. DigiFab has

The company said that the needles of pre-filled syringes, penetrating the needle shield, put sterility of needle and product at risk, as well as endanger medical staff. A

MyoCell has been tested on patients in four clinical trials. TheRegen trial is designed to test the safety and effectiveness of a composition of muscle stem cells that

5P12-RANTES is a microbicides, developed with a purpose of preventing HIV from spreading. The clinical trial will be conducted to prove the safety of the microbicide. The company

Cobalamin is Access’ proprietary technology based upon the use of vitamin B12 for targeted delivery of drugs to disease sites and for oral drug delivery of drugs that